Business Context and Reporting Period
This Form 8-K Current Report was filed by OraSure Technologies, Inc. on May 26, 2022, covering events occurring on May 20, 2022. The filing primarily addresses significant changes in executive leadership, specifically the appointment of a new President and Chief Executive Officer (CEO) and the resignation of a senior executive.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes and Executive Compensation
Appointment of Carrie Eglinton Manner
- Role: Appointed President and CEO, effective June 4, 2022. She will also join the Board of Directors as a Class I director.
- Succession: She succeeds Dr. Nancy J. Gagliano, who will resign as Interim CEO on the effective date.
- Base Salary: $700,000 annually.
- Annual Incentive: Target amount of at least 100% of base salary.
- Equity Awards (Inducement):
- Restricted Stock/RSU valued at $4,000,000 (vests in 2 years).
- Restricted Stock/RSU valued at $1,600,000 (vests in 3 equal annual installments).
- Performance-based RSU valued at $1,600,000 (subject to performance conditions).
- Severance (No Cause/Good Reason): 18 months base salary + 150% target bonus + 50% accelerated vesting of time-based awards.
- Severance (Change of Control): 24 months base salary + 200% target bonus + full accelerated vesting of time-based awards.
Resignation of Kathleen G. Weber
- Role: President of Molecular Solutions.
- Effective Date: Resignation planned for August 21, 2022.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. The primary risk disclosed relates to the transition of leadership and the significant financial obligations associated with the new CEO's employment agreement, including substantial equity grants and severance provisions.
Investor Verification Checklist
- Verify the exact number of shares granted in the equity awards based on the "Trailing Average Price" of the stock on the grant date.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Good Reason," "Change of Control," and performance metrics.
- Confirm the timeline for Dr. Nancy J. Gagliano's transition out of the Interim CEO role.
- Assess the impact of Kathleen G. Weber's departure on the Molecular Solutions division.